Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27531597
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Cutan+Pathol
2016 ; 43
(11
): 989-993
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52
therapy (alemtuzumab)
#MMPMID27531597
Clark SL
; Tse JY
; Fisher DC
; LeBeouf NR
; Murphy GF
; Kupper TS
; Clark RA
; Lian CG
J Cutan Pathol
2016[Nov]; 43
(11
): 989-993
PMID27531597
show ga
BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed against CD52,
a cell surface antigen on B and T lymphocytes, and used to treat B-cell chronic
lymphocytic leukemia and cutaneous T-cell lymphoma. Skin rash is a common adverse
reaction following treatment with alemtuzumab. However, the clinicopathologic
features and immunologic basis for the reaction have not been previously
reported. METHODS: Our hospital's electronic pathology database was searched for
cases with documentation of 'alemtuzumab' or 'anti-CD52' in the clinical history
provided by either the ordering physician or the pathologist. Clinical and
histopathologic review of the cases was performed. RESULTS: Five patients with
cutaneous T-cell lymphoma (CTCL) or chronic lymphocytic leukemia (CLL) were
treated with alemtuzumab, and developed pruritic, erythematous papules and
plaques. Histopathology of the skin lesions revealed subacute spongiotic
dermatitis with multifocal parakeratosis, endothelial activation and perivascular
lymphocytic infiltrate. Eosinophils were not a prominent feature. CONCLUSIONS: We
describe the clinicopathologic features of a novel hypersensitivity reaction to
alemtuzumb, and hypothesize it may be due to an immunologic response precipitated
by the persistence of resident memory T-cells (T(RM) ) in the skin. Our findings
raise awareness for a novel reaction pattern and guide the histopathologic
interpretation of lesions which may clinically mimic residual or recurrent
cutaneous lymphoproliferative disorders.